vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Company Growth (employees)
Type
Public
HQ
High Point, US
Founded
1998
Size (employees)
51 (est)-20%
vTv Therapeutics was founded in 1998 and is headquartered in High Point, US

vTv Therapeutics Office Locations

vTv Therapeutics has office in High Point
High Point, US

vTv Therapeutics Metrics

vTv Therapeutics Summary

Market capitalization

$58.8 m

Closing share price

$6.1
vTv Therapeutics's current market capitalization is $58.8 m.

vTv Therapeutics Financials

vTv Therapeutics's revenue is $634 k in FY, 2016
FY, 2016

Revenue

$634 k

Net Income

($55.4 m)

vTv Therapeutics Market Value History

vTv Therapeutics Company Life

You may also be interested in